New insight into the molecular drug target of diabetic nephropathy

Wawaimuli Arozal; Melva Louisa; Rianto Setiabudy

doi:10.1155/2014/968681

New insight into the molecular drug target of diabetic nephropathy

Vivian, Wawaimuli Arozal, Melva Louisa, Rianto Setiabudy

Department of Pharmacology and Therapeutic Pre Clinic

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

Abstract

Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.

Original language	English
Article number	968681
Journal	International Journal of Endocrinology
Volume	2014
DOIs	https://doi.org/10.1155/2014/968681
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2014/968681

Cite this

@article{da904dda029e485885dbb0bf31249d31,

title = "New insight into the molecular drug target of diabetic nephropathy",

abstract = "Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.",

author = "Vivian and Wawaimuli Arozal and Melva Louisa and Rianto Setiabudy",

year = "2014",

doi = "10.1155/2014/968681",

language = "English",

volume = "2014",

journal = "International Journal of Endocrinology",

issn = "1687-8337",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - New insight into the molecular drug target of diabetic nephropathy

AU - Vivian, null

AU - Arozal, Wawaimuli

AU - Louisa, Melva

AU - Setiabudy, Rianto

PY - 2014

Y1 - 2014

N2 - Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.

AB - Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84895195797&partnerID=8YFLogxK

U2 - 10.1155/2014/968681

DO - 10.1155/2014/968681

M3 - Review article

AN - SCOPUS:84895195797

SN - 1687-8337

VL - 2014

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

M1 - 968681

ER -

New insight into the molecular drug target of diabetic nephropathy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this